CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia. Issue 1 (31st January 2022)

• Record Type: Journal Article
• Authors: Herrmann, Nathan; Ismail, Zahinoor; Collins, Rhonda; Desmarais, Philippe; Goodarzi, Zahra; Henri‐Bhargava, Alexandre; Iaboni, Andrea; Kirkham, Julia; Massoud, Fadi; Moser, Andrea; Silvius, James; Watt, Jennifer; Seitz, Dallas
• Is Part Of: Alzheimer's & dementia. Volume 8:Issue 1(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-01-31
• Subjects: cholinesterase inhibitor -- memantine -- cognitive enhancer -- dementia -- deprescribing -- discontinuation; Dementia -- Periodicals; Dementia -- Treatment -- Periodicals; Alzheimer's disease -- Treatment -- Periodicals; Alzheimer's disease -- Periodicals; 616.831
• DOI: 10.1002/trc2.12099
• Languages: English
• ISSNs: 2352-8737

Abstract

Abstract: Introduction: Cognitive enhancers (ie, cholinesterase inhibitors and memantine) can provide symptomatic benefit for some individuals with dementia; however, there are circumstances in which the risks of continuing treatment may potentially outweigh benefits. The decision to deprescribe cognitive enhancers must consider each patient's preferences, treatment indications, current clinical status and symptoms, prognosis, and dementia type. Methods: The 5th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD5) established a subcommittee of experts to review current evidence on the deprescribing of cognitive enhancers. The questions answered by this group included: When should cognitive enhancers be deprescribed in persons with dementia and mild cognitive impairment? How should cognitive enhancers be deprescribed? And, what clinical factors should be considered when deprescribing cognitive enhancers? Results: Patient and care‐partner preferences should be incorporated into all decisions to deprescribe cognitive enhancers. Cognitive enhancers should be discontinued in individuals without ongoing evidence of benefit or when the indication for cognitive enhancer use was inappropriate (eg, mild cognitive impairment). Deprescribing should occur gradually and cognitive enhancers should be reinitiated if patients' cognition or function deteriorates. Cognitive enhancers should be continued in individuals whose neuropsychiatric symptoms improve in response to treatment. Clinicians should not deprescribe cognitive enhancers in individuals with significant neuropsychiatric symptoms until symptoms have stabilized. Conclusion: CCCDTD5 deprescribing recommendations provide evidence‐informed recommendations related to cognitive enhancer deprescribing that will facilitate shared decision making among patients, care partners, and clinicians.